Third-quarter sales grew 5% for Amersham, the parent company of pharmaceutical provider Amersham Health of Buckinghamshire, U.K. Excluding discontinued products and using constant exchange rates, the company reported sales of £393 million ($669.1 million U.S.) for its fiscal 2003 third quarter, an increase of 5% compared with the £378 million ($643.4 million) posted for the third quarter of fiscal 2002.
The firm reported sales of £1.2 billion ($2.043 billion) for its first three quarters of 2003, a 6% increase compared with the £1.19 billion ($2.025 billion) for the same period last year. Sales for Amersham Health were £235 million ($400 million) for the period (end-September 30), a 6% increase from last year.
The company said it enjoyed strong growth in its patented product portfolio, which was up 19%. Amersham’s Visipaque iso-osmolar continues to do well, thanks to a positive study published in February on the product’s low rate of contrast-induced reactions compared to a low-osmolar agent.
By AuntMinnie.com staff writersOctober 30, 2003
Related Reading
Amersham adds new contrast packaging, October 30, 2003
Amersham re-ups with Novation, October 24, 2003
GE makes $9.8 billion bid for Amersham, October 10, 2003
GE rumored to be courting Amersham, October 10, 2003
Visipaque sales surge at Amersham, August 6, 2003
Copyright © 2003 AuntMinnie.com
